HF. [7] [8] [9] [10] [11] However, there is currently no information available on the effects of cardiac surgery on SAS in HF patients. In this study, we examined the relationships between HF with valvular heart diseases and OSA and CSA. We further investigated the effects of valve repair surgery on OSA and CSA in patients with severe valvular diseases and HF.
Methods

Study Design and Patient Selection
A schematic representation of the study is provided in Figure 1 . Data were collected from 150 patients with HF (New York Heart Association (NYHA) class II or III) and with severe mitral valvular (MV) and/or aortic valvular (AV) heart diseases. Patients were recruited on the basis of diagnoses by echocardiography and cardiac catheterization between July 2005 and March 2008 at Matsumoto Kyoritsu Hospital. Each patient was diagnosed and underwent optimal therapy prior to the study, and was on at least 2 weeks of stable medication, as confirmed by a cardiologist. Exclusion criteria included the inability to undergo polysomnography (PSG) as a result of severe HF (NYHA class IV), and a diagnosis of acute coronary syndrome within the prior 2 weeks. Written informed consent was obtained from each patient prior to participation. This study was approved by the Institutional Review Board of the Matsumoto Kyoritsu Hospital.
PSG analyses were used to divide patients into 2 groups: SAS (n=103, apnea-hypopnea index (AHI) ≥20 /h of sleep) and mild-to-no sleep apnea (M-NSA) (n=47, AHI <20 /h of sleep). The AHI cutoff of 20 /h was chosen to conform to that used in previous studies in which mortality risk was associated with OSA, 12 and to abide by the guidelines of Japanese Respiratory Society to treat severe OSA patients with CPAP therapy. Among 103 HF patients with SAS, 92 patients received valve repair surgery and 74 patients were reassessed (Figure 1) . To select patients receiving surgery, the criteria published by ACC/AHA 13,14 was used.
Patient Assessments
Body mass index (BMI) was calculated as the weight (kg) divided by the square of the height (m). Hypertension was defined as elevation of blood pressure levels (≥140/ 90 mmHg) or antihypertensive treatment at the time of participation in the study. Diabetes mellitus was defined as elevation in fasting blood glucose levels (≥126 mg/dl) or pharmacological treatments. Hyperlipidemia was defined as elevation in fasting levels of serum cholesterol (≥220 mg/dl) and triglycerides (≥150 mg/dl), and decrease in HDLcholesterol (<40 mg/dl). Echocardiography (iE33, Philips) was performed to assess left ventricular ejection fraction (LVEF), left ventricular diameter in the diastolic phase (LVDd) and tricuspid regurgitation. Right cardiac catheterization (via the transbrachial approach) was carried out Study profile: 150 patients with heart failure (HF) (New York Heart Association class II and III) and with mitral valvular and/or aortic valvular heart diseases were enrolled. Based on the polysomnography data, the patients were divided into 2 groups: sleep apnea syndrome (SAS) (n= 103, apnea-hypopnea index (AHI) ≥20) and mildto-no sleep apnea (M-NSA) (n=47, AHI <20). Among 103 HF patients with SAS, 92 patients underwent valve repair surgery and 74 patients were reassessed. sleep. The absence of airflow in the upper airway with and without ribcage and/or abdominal movement was defined as obstructive and central apnea, respectively. CSA-apnea index (AI) and OSA-AI were computed as the number of central and obstructive apnea events, respectively, per hour of sleep.
Statistical Analysis
Data are presented as the mean ± SD. Pre-and post-surgery measurements were compared via paired t-tests. Unpaired t-tests and Mann-Whitney tests were used to evaluate differences for independent groups on continuous variables. Categorical variables were assessed using chi-squared tests. All analyses were performed using StatView software (Abacus Concepts, Inc, Berkley, CA, USA). P<0.05 was considered to be statistically significant.
Results
Patient Characteristics
We enrolled 150 patients (68.7±9.7 years, 92 men) with HF (NYHA class II and III), including MV and/or AV heart diseases (56 MV, 78 AV, 16 MV+AV, Table 1 ). Figure 2 displays the relationships between SAS and cardiac function as determined by echocardiography and right cardiac catheterization. The SAS group was significantly associated with the LVDd (50.6±9.4 vs 47.6±8.4, P=0.048) (Figure 2) . However, there was no significant Values are n or mean ± SD. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
SAS and Cardiac Function
Other abbreviations see in Table 2 . Values are n (%) or mean ± SD. PCWP, pulmonary capillary wedge pressure; PAP, pulmonary artery pressure. Other abbreviations see in Table 2 . association with LVEF (P=0.191), PCWP (P=0.146) and mean PAP (P=0.081) between the SAS and M-NSA groups (Figures 2C,D) . Because the SAS group contained both CSA and OSA patients, we next evaluated the correlations amongn LVDd, LVEF, PCWP or mean PAP and CSA-AI or OSA-AI. We found that there were significant relationships between CSA-AI and PCWP (r=0.632, P<0.001) or mean PAP (r=0.423, P=0.006). Similar relationships were not identified for OSA-AI.
Effects of Valve Repair Surgery
Valve repair surgery was performed in 74 patients with HF whose characteristics are described in Table 3 . Mitral valve, aortic, and both mitral and aortic surgery was performed in 20, 41 and 13 patients, respectively. (Figure 3 ).
Discussion
We report significant associations between SAS and age, gender, BMI and hypertension in HF patients with valvular disease. The CSA-AI, but not the OSA-AI, significantly correlated in these patients with the parameters of cardiac function, such as LVDd, EF, PCWP and mean PAP. Moreover, valve repair surgery considerably improved not only the parameters of cardiac function, but also the CSA-AI. These results suggest that improvement of cardiac function with surgery may reduce the severity of CSA in HF patients with severe MV and/or AV diseases. Central apnea is characterized by apneic events during sleep with no associated ventilatory effort. 4, 15 Periodic breathing, or nonhypercapnic CSA, is triggered by oscillations in respiratory drive induced by hyperventilation during nonrapid eye movement sleep when respiratory control is under a chemically controlled, negative-feedback loop. The most common form of CSA is manifest in patients with congestive CHF, and is termed Cheyne-Stokes respiration. Several reports have described the correlation between HF and CSA, and have suggested that CSA exacerbates HF and predicts mortality in systolic HF. 16 However, it has not been determined whether CSA is epiphenomenal in the context of HF or whether it directly increases HF risk. 4, 17, 18 In the present study, we found that CSA correlated with parameters of cardiac function in HF patients with valvular diseases. In addition, multivariate analysis showed that CSA-AI was associated with LVEF (P<0.0001) and PCWP (P=0.0051). Consistent with our findings, Solin et al 19 reported that PCWP and PAP were elevated in HF patients with CSA compared to those with OSA or without apnea, and that a significant correlation exists between PCWP and central apnea frequency and severity in HF patients with CSA. Therefore, we hypothesized that improvements in cardiac function would lead to improvements in CSA and this was confirmed by the present study.
The standard treatment for CSA includes nocturnal oxygen therapy, 20 ,21 yet several investigations have indicated that CSA can be alleviated via treatment of the underlying disease. In particular, recent studies have shown that treatment of HF could specifically improve CSA. For instance, Sinha et al 8 reported that CRT leads to a reduction of CSA and to increased sleep quality in patients with HF and SAS. Kara et al 11 also reported that CRT reduced the severity of CSA in the short term, and that this reduction correlated significantly with the CRT-mediated reduction of mitral regurgitation. Furthermore, Tamura et al 22, 23 demonstrated that treatment with β-blocker reduced the severity of CSA in patients with chronic HF. Although there are no reports describing a relationship between CSA and valvular heart diseases, 2 case reports suggest that CSA is improved by mitral valve replacement or valvuloplasty. 24, 25 In the present study, we found that surgical correction in a subset of patients with valvular diseases resulted in a remarkable reduction in CSA, but not OSA.
Differences between stenosis and regurgitation do not pose difficulties for the present findings. There were no differences related to valvular disease for the severity of SAS, right cardiac pressure or the level of improvement of CSA during the investigation period. Therefore, it is reasonable to assume that the improvements in CSA as a result of CHF treatment can occur regardless of the surgical method used.
Study Limitations
First, although PSG is regarded as the 'gold standard' in diagnosing SAS, we performed a single-night PSG. Second, long-term outcomes (eg, quality of life, mortality) for our surgical patients could not be determined because of the relatively brief follow-up period. Third, because this study included all types of MV and AV diseases and some types of surgical procedures, we should be cautious about the interpretation of this study. Finally, HF and valvular disease are not the sole causes of CSA, but the exact mechanisms responsible are not clearly defined by the present study.
In conclusion, our findings suggest close associations between CSA, but not OSA, and cardiac function in HF patients with MV and/or AV diseases. Furthermore, improvement of cardiac function with valve repair surgery reduces the severity of CSA in HF patients with MV and/or AV diseases.
